BioStem Technologies files S-1 for resale of up to 3.57 million shares
The Florida-based tissue allograft maker disclosed going-concern doubt tied to CMS reimbursement cuts, BioTissue-related obligations, and an existing loan.
BioStem Technologies, Inc. filed a Form S-1 with the Securities and Exchange Commission on July 29, 2026, registering the resale of up to 3,571,429 shares of common stock held by a single selling stockholder. The shares consist of 746,269 shares issued under a Securities Purchase Agreement dated May 21, 2026, plus up to 2,825,160 additional shares that may be issued under the agreement's anti-dilution adjustment provisions, assuming the maximum adjustment at a floor price of $0.70 per share1. The company said it will not receive any proceeds from these resales.
The Pompano Beach, Florida company develops perinatal tissue-based therapies that support healing across the continuum of care, including advanced wound care and surgical applications1. On January 21, 2026, it closed an acquisition of surgical and wound care assets from BioTissue Holdings, including the Neox® and Clarix® trademarks as well as two patents relating to technologies focused on certain orthopedic therapies1.
The filing discloses going-concern doubt. The company said it expects to incur losses and negative cash flows from operations, due to recent changes to product pricing determined by CMS and contractual obligations over the next twelve months related to the BioTissue acquisition, including the Clearance Payment and an existing loan1. As a result, the company's independent registered public accounting firm included an explanatory paragraph in its report expressing substantial doubt about the company's ability to continue as a going concern1.
On the reimbursement front, CMS issued a final rule on October 31, 2025 replacing the prior ASP + 6% Medicare reimbursement methodology with a flat $127.14 per square centimeter rate effective January 1, 2026, which the company said decreased its revenue per square centimeter in the physician office setting by up to 95% in some cases1.
For the year ended December 31, 2025, BioStem reported a net loss of $6.6 million and an accumulated deficit of $21.2 million1. Common stock is quoted on the OTCID under "BSEM," and the company has applied to list on the Nasdaq Capital Market1 under the same symbol.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.